<DOC>
	<DOCNO>NCT02337595</DOCNO>
	<brief_summary>The stud evaluate whether infusion CD45RA-depleted lymphocyte donor early post-transplant safe way improve immunity common infection recipient TCR-alpha/beta deplete hematopoietic stem cell graft .</brief_summary>
	<brief_title>Memory T-cell Infusion Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Graft-versus-host disease ( GVHD ) remain important direct complication hematopoietic stem cell transplantation . Methods use prevent GVHD include diverse pharmacologic intervention ex vivo method T-cell depletion , latter effective one . Historically depletion T-cells graft associate increased rate graft failure , relapse malignant disease prolong immune deficiency . Selective depletion TCR-alpha/beta T-lymphocytes new method hematopoietic stem cell graft manipulation think conserve important cell population , e.g . NK cell gamma/delta T cell within graft . Preliminary result suggest TCR alpha/beta depletion ensure high engraftment rate , low early mortality good control GVHD . The problem delay immune reconstitution life-threatening viral infection remain incompletely resolve . Depletion naive ( CD45RA-positive ) T-cells develop new method graft manipulation prevent GVHD . Research data indicate alloreactivity associate mainly naive T-cell fraction . In vitro depletion CD45RA lower significantly alloreactive response retain reactivity pathogen . In current protocol plan test whether relatively low dos CD45RA-depleted mononuclear cell safely infuse TCR-alpha/beta depleted transplantation . The biologic readout protocol quantitative assessment T-cell reactivity common pathogens infusion .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Opportunistic Infections</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>recipient allogeneic hematopoietic stem cell graft haploidentical match unrelated donor TCR alpha/beta depletion hematopoietic stem cell graft CMVseropositive donor stable hematopoietic engraftment active graftversushost disease grade 24 systemic immune suppressive therapy except calcineurin inhibitor monotherapy uncontrolled sepsis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CD45RA-depletion</keyword>
	<keyword>TCR-alpha/beta depletion</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>immune reconstitution</keyword>
	<keyword>Graft Enhancement , Immunologic</keyword>
	<keyword>Immunocompromized Host</keyword>
</DOC>